Tang X, et al. - Searching the Cochrane library, PubMed, and EMBASE databases, researchers identified and analyzed seven randomized controlled trials with a total of 1,287 patients to assess the benefits of EGFR inhibitors in head and neck squamous cell carcinoma (HNSCC) patients. Outcomes indicate that gefitinib does not extend overall survival and progression free survival or improve overall response rate. Incidence of skin toxicity and diarrhea were higher with gefitinib for patients with advanced HNSCC. However, gefitinib alone is comparable to methotrexate or methotrexate + fluorouracil and leads to better quality-of-life for recurrent patients.